Cisatracurium Besylate Injection
Product Images NDC 68083-488

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 68083-488). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cisatracurium-spl-carton-label-10ml (Cisatracurium Spl Carton Label 10ml)

Packaging label for Cisatracurium Besylate Injection, USP, 20 mg/10 mL (2 mg/mL) for intravenous use. The label indicates it is a paralyzing agent with 0.9% benzyl alcohol as a preservative. It is supplied as a 10 mL multiple-dose vial by Gland Pharma Limited, India. The label includes storage instructions, usage warnings, and an NDC barcode.*

FDA Label Image

Cisatracurium-spl-carton-label-20ml (Cisatracurium Spl Carton Label 20ml)

Packaging label for Cisatracurium Besylate Injection, USP 200 mg/20 mL (10 mg/mL), an intravenous injection by Gland Pharma Limited. The label states it is a paralyzing agent for ICU use only, supplied in a 20 mL single-dose vial. It includes warnings about respiratory arrest and instructions to discard unused portions.*

FDA Label Image

Cisatracurium-spl-carton-label-5ml (Cisatracurium Spl Carton Label 5ml)

Carton packaging label for Cisatracurium Besylate Injection USP 10 mg/5 mL (2 mg/mL) by Gland Pharma Limited. The label states it is for intravenous injection supplied as a 5 mL single-dose vial. It includes warnings about the drug being a paralyzing agent and storage instructions to keep at 2° to 8°C. The label also notes that unused portions should be discarded.*

FDA Label Image

Cisatracurium-spl-map-figure-2 (Cisatracurium Spl Map Figure 2)

A scatter plot chart showing data points distributed around the origin on two axes labeled with percentage changes. The vertical axis is labeled with heart rate (HR) ranging from -60% to +60%, and the horizontal axis is labeled with mean arterial pressure (MAP) also ranging from -60% to +60%. The plot depicts variability in HR and MAP percentage changes in relation to a baseline.*

FDA Label Image

Cisatracurium-spl-map-figure-3 (Cisatracurium Spl Map Figure 3)

A scatter plot chart depicting data points with axes labeled MAP (mean arterial pressure) on the horizontal axis and HR (heart rate) on the vertical axis, each ranging from -60% to +60%. The chart shows data variability around the center point with no specific trend highlighted.*

FDA Label Image

Cisatracurium-spl-sticker-label-10ml (Cisatracurium Spl Sticker Label 10ml)

Cisatracurium Besylate Injection, USP label panel featuring a warning that the drug is a paralyzing agent causing respiratory arrest. The dosage strength is partially visible with mg/mL indicated. The label background is red with black text.*

FDA Label Image

Cisatracurium-spl-sticker-label-20ml (Cisatracurium Spl Sticker Label 20ml)

Label of Cisatracurium Besylate Injection, USP, a paralyzing agent with a warning about causing respiratory arrest. The dosage strength placeholder is shown as mg/mL on a red background. The label includes a prominent safety warning about the drug's paralytic effects.*

FDA Label Image

Cisatracurium-spl-sticker-label-5ml (Cisatracurium Spl Sticker Label 5ml)

Label for Cisatracurium Besylate Injection, USP in an injection dosage form. The label, with a red background, includes a warning that this product is a paralyzing agent that causes respiratory arrest. The strength is indicated in mg/mL but is not fully visible. The label highlights the serious warning prominently.*

FDA Label Image

Cisatracurium-spl-structure (Cisatracurium Spl Structure)

Chemical structure diagram of cisatracurium besylate, illustrating the molecular composition including aromatic rings, methoxy groups, and a besylate counter ion.*

FDA Label Image

Cisatracurium-spl-vial-label-10ml (Cisatracurium Spl Vial Label 10ml)

Label for Cisatracurium Besylate Injection, USP, 20 mg/10 mL (2 mg/mL) in a 10 mL multiple-dose vial. It highlights the active ingredient cisatracurium besylate with 0.9% benzyl alcohol as a preservative. Label includes a warning for paralysis and respiratory arrest, storage instructions at 2° to 8°C, and manufacturer information for Gland Pharma Limited, Hyderabad, India.*

FDA Label Image

Cisatracurium-spl-vial-label-20ml (Cisatracurium Spl Vial Label 20ml)

Label for Cisatracurium Besylate Injection, USP, 200 mg/20 mL (10 mg/mL) intravenous injection by Gland Pharma Limited. The sterile, nonpyrogenic product is supplied in a 20 mL single-dose vial. The label includes warnings about its paralytic effects and requirement for ICU use, storage instructions, and manufacturer details with barcodes.*

FDA Label Image

Cisatracurium-spl-vial-label-5ml (Cisatracurium Spl Vial Label 5ml)

Label for Cisatracurium Besylate Injection, USP, showing 10 mg per 5 mL (2 mg/mL) strength in a 5 mL single-dose vial. It is sterile, nonpyrogenic, for intravenous injection, and labeled as a paralyzing agent with a warning for respiratory arrest. Manufactured by Gland Pharma Limited, Hyderabad, India. Storage instructions and lot/expiration placeholders are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.